Featured Publications
The Lymphatic System in Kidney Disease
Baker M, Cantley L. The Lymphatic System in Kidney Disease. Kidney360 2023, 4: e841-e850. PMID: 37019177, PMCID: PMC10371377, DOI: 10.34067/kid.0000000000000120.Peer-Reviewed Original ResearchConceptsKidney diseaseLymphatic systemSetting of AKIKidney allograft rejectionNormal kidney functionImmune response modulationAllograft rejectionLymph nodesInflammatory infiltrateKidney functionImmune cellsTissue edemaNovel therapiesImmune surveillanceNumerous disease statesSystemic circulationFluid removalKidney tissueResident cellsTherapeutic potentialSurveillance cellsAKIDisease statesKidneyResponse modulationNSAIDs in CKD: Are They Safe?
Baker M, Perazella MA. NSAIDs in CKD: Are They Safe? American Journal Of Kidney Diseases 2020, 76: 546-557. PMID: 32479922, DOI: 10.1053/j.ajkd.2020.03.023.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsNonsteroidal anti-inflammatory drugsChronic kidney diseaseGlomerular filtration rateFiltration rateRisk factorsHigh pain burdenAcute kidney injuryManagement of painAnti-inflammatory drugsCKD populationNSAID useKidney injuryPain burdenPain controlHeart failureComorbid conditionsElectrolyte derangementsKidney diseaseSafety dataDrug effectsPatientsIndividualized basisDrug metabolismProgressive lossCautious useMortality after acute kidney injury and acute interstitial nephritis in patients prescribed immune checkpoint inhibitor therapy
Baker ML, Yamamoto Y, Perazella MA, Dizman N, Shirali AC, Hafez N, Weinstein J, Simonov M, Testani JM, Kluger HM, Cantley LG, Parikh CR, Wilson FP, Moledina DG. Mortality after acute kidney injury and acute interstitial nephritis in patients prescribed immune checkpoint inhibitor therapy. Journal For ImmunoTherapy Of Cancer 2022, 10: e004421. PMID: 35354588, PMCID: PMC8968986, DOI: 10.1136/jitc-2021-004421.Peer-Reviewed Original ResearchConceptsAcute interstitial nephritisAcute kidney injuryImmune checkpoint inhibitor therapyCheckpoint inhibitor therapyICI therapyKidney injuryInhibitor therapyInterstitial nephritisTime-varying Cox proportional hazards modelsHigher peak serum creatinineSevere acute kidney injuryCancer typesCox proportional hazards modelAssociations of biopsyBaseline laboratory valuesObservational cohort studyPeak serum creatinineFavorable treatment responseProportional hazards modelAKI patientsTherapy initiationCohort studySerum creatinineUnivariable analysisImmune activation
2023
Incidence and outcomes of acute kidney injury including hepatorenal syndrome in hospitalized patients with cirrhosis in the US
Patidar K, Belcher J, Regner K, St. Hillien S, Simonetto D, Asrani S, Neyra J, Sharma P, Velez J, Wadei H, Nadim M, Chung R, Seethapathy R, Parada X, Ouyang T, Ufere N, Robinson J, Diaz P, Wilechansky R, Przybyszewski E, Smith T, Ali A, Orman E, Schulz P, Siddiqui S, Shabbir R, Liu L, Cama-Olivares A, Flannery A, Baker M, Gunasekaran D, Aswine A, Issa R, Li J, Verma S, Chalmers D, Varghese V, Lam W, Mohamed M, Kovacic R, Gaddy A, Attieh R, Cortes P, Semnani S, Wang L, Khemichian S, Allegretti A, consortium F. Incidence and outcomes of acute kidney injury including hepatorenal syndrome in hospitalized patients with cirrhosis in the US. Journal Of Hepatology 2023, 79: 1408-1417. PMID: 37517455, PMCID: PMC10807505, DOI: 10.1016/j.jhep.2023.07.010.Peer-Reviewed Original ResearchConceptsEtiology of AKIHRS-AKISubdistribution hazard ratiosHepatorenal syndromePrerenal AKIKidney injuryHigh morbidityIncidence ratePractice patternsSimilar outcomesHigher AKI stageAcute kidney injuryRetrospective cohort studyAcute tubular necrosisConsecutive adult patientsEtiology of injuryAKI stageAKI definitionLiver transplantAdult patientsCohort studyHazard ratioSevere complicationsTubular necrosisComplete responsePersonalised recommendations for hospitalised patients with Acute Kidney Injury using a Kidney Action Team (KAT-AKI): protocol and early data of a randomised controlled trial
Aklilu A, O’Connor K, Martin M, Yamamoto Y, Coronel-Moreno C, Shvets K, Jones C, Kadhim B, Corona-Villalobos C, Baker M, Tan J, Freeman N, Groener M, Menez S, Brown D, Culli S, Lindsley J, Orias M, Parikh C, Smith A, Sundararajan A, Wilson F. Personalised recommendations for hospitalised patients with Acute Kidney Injury using a Kidney Action Team (KAT-AKI): protocol and early data of a randomised controlled trial. BMJ Open 2023, 13: e071968. PMID: 37068906, PMCID: PMC10111926, DOI: 10.1136/bmjopen-2023-071968.Peer-Reviewed Original ResearchConceptsPrimary teamAcute Kidney Injury OutcomesAKI alert systemInvestigator-blinded trialUsual care armKey secondary outcomesClinical decision support toolIntensive care unitUS hospital systemAKI alertsAKI detectionAKI progressionCare armSecondary outcomesPrimary outcomeCare unitMedian timeMedical floorPercentage of recommendationsDiagnostic interventionsInjury outcomesRandomisationHospital systemEthics CommitteeDedicated team
2022
Strongyloides stercoralis infection identified on urine microscopy
Baker ML, Brewster UC. Strongyloides stercoralis infection identified on urine microscopy. BMJ Case Reports 2022, 15: e250078. PMID: 35379686, PMCID: PMC8981339, DOI: 10.1136/bcr-2022-250078.Peer-Reviewed Case Reports and Technical Notes
2020
Can NSAIDs Be Used Safely for Analgesia in Patients with CKD?: COMMENTARY.
Baker ML, Perazella MA. Can NSAIDs Be Used Safely for Analgesia in Patients with CKD?: COMMENTARY. Kidney360 2020, 1: 1192-1194. PMID: 35372870, PMCID: PMC8815502, DOI: 10.34067/kid.0004652020.Commentaries, Editorials and LettersSGLT2 inhibitor therapy in patients with type-2 diabetes mellitus: is acute kidney injury a concern?
Baker ML, Perazella MA. SGLT2 inhibitor therapy in patients with type-2 diabetes mellitus: is acute kidney injury a concern? Journal Of Nephrology 2020, 33: 985-994. PMID: 32067179, DOI: 10.1007/s40620-020-00712-5.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsType 2 diabetes mellitusAcute kidney injuryChronic kidney diseaseDiabetes mellitusKidney diseaseKidney injuryAlbuminuric chronic kidney diseaseEnd-stage kidney diseaseInhibitor drugsSGLT2 inhibitor therapySignificant cardiovascular benefitsHeart failure hospitalizationGlomerular filtration rateAtherosclerotic cardiovascular diseaseLarge clinical trialsFDA adverse eventsBeneficial cardiovascularKidney benefitsSGLT2 transporterCardiovascular deathFailure hospitalizationAdverse eventsCardiovascular benefitsKidney protectionBlood pressure
2019
Outcomes of Guideline-Directed Concomitant Annuloplasty for Functional Tricuspid Regurgitation
Brescia AA, Ward ST, Watt TMF, Rosenbloom LM, Baker M, Khan S, Ziese E, Romano MA, Bolling SF, Group M. Outcomes of Guideline-Directed Concomitant Annuloplasty for Functional Tricuspid Regurgitation. The Annals Of Thoracic Surgery 2019, 109: 1227-1232. PMID: 31479635, PMCID: PMC7048637, DOI: 10.1016/j.athoracsur.2019.07.035.Peer-Reviewed Original ResearchConceptsConcomitant tricuspid valve repairTricuspid valve repairRecurrent tricuspid regurgitationTricuspid regurgitationFunctional tricuspid regurgitationValve repairConcomitant coronary artery bypassLeft-sided valve surgeryPreoperative atrial fibrillationWorse tricuspid regurgitationCoronary artery bypassRight ventricular remodelingSafety end pointRight ventricular performanceComplex aortic surgeryPreoperative tricuspid regurgitationRight ventricular dimensionsFear of complicationsFunctional mitral regurgitationActive endocarditisAortic surgeryArtery bypassValve surgeryConsecutive patientsPacemaker placement
2017
Cardiac Resynchronization Therapy—Does One Size Fit All?: A Teachable Moment
Baker M, Weidendorf D, Swaminathan L. Cardiac Resynchronization Therapy—Does One Size Fit All?: A Teachable Moment. JAMA Internal Medicine 2017, 177: 1513-1514. PMID: 28846770, DOI: 10.1001/jamainternmed.2017.2778.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus Statements